|
mutLBSgeneDB |
| |
| |
| |
| |
| |
| |
|
| Gene summary for PPP2R3B |
 Gene summary |
| Basic gene Info. | Gene symbol | PPP2R3B |
| Gene name | protein phosphatase 2, regulatory subunit B'', beta | |
| Synonyms | NYREN8|PPP2R3L|PPP2R3LY|PR48 | |
| Cytomap | UCSC genome browser: Xp22.33; Yp11.3 | |
| Type of gene | protein-coding | |
| RefGenes | NM_013239.4, NM_199326.1, | |
| Description | NY-REN-8 antigenPP2A, subunit B, PR48 isoformprotein phosphatase 2 (formerly 2A), regulatory subunit B'', betaserine/threonine protein phosphatase 2A, 48kDa regulatory subunit Bserine/threonine-protein phosphatase 2A regulatory subunit B'' subunit bet | |
| Modification date | 20141207 | |
| dbXrefs | MIM : 300339 | |
| HGNC : HGNC | ||
| Ensembl : ENSG00000167393 | ||
| HPRD : 02276 | ||
| Vega : OTTHUMG00000021052 | ||
| Protein | UniProt: Q9Y5P8 go to UniProt's Cross Reference DB Table | |
| Expression | CleanEX: HS_PPP2R3B | |
| BioGPS: 28227 | ||
| Pathway | NCI Pathway Interaction Database: PPP2R3B | |
| KEGG: PPP2R3B | ||
| REACTOME: PPP2R3B | ||
| Pathway Commons: PPP2R3B | ||
| Context | iHOP: PPP2R3B | |
| ligand binding site mutation search in PubMed: PPP2R3B | ||
| UCL Cancer Institute: PPP2R3B | ||
| Assigned class in mutLBSgeneDB | C: This gene just belongs to mutLBSgenes. | |
| Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez |
| GO ID | GO Term | PubMed ID |
| Top |
| Ligand binding site mutations for PPP2R3B |
| Cancer type specific mutLBS sorted by frequency |
| LBS | AAchange of nsSNV | Cancer type | # samples | D329,D327 | T328M | UCEC | 1 |
| cf) Cancer type abbreviation. BLCA: Bladder urothelial carcinoma, BRCA: Breast invasive carcinoma, CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma, COAD: Colon adenocarcinoma, GBM: Glioblastoma multiforme, LGG: Brain lower grade glioma, HNSC: Head and neck squamous cell carcinoma, KICH: Kidney chromophobe, KIRC: Kidney renal clear cell carcinoma, KIRP: Kidney renal papillary cell carcinoma, LAML: Acute myeloid leukemia, LUAD: Lung adenocarcinoma, LUSC: Lung squamous cell carcinoma, OV: Ovarian serous cystadenocarcinoma, PAAD: Pancreatic adenocarcinoma, PRAD: Prostate adenocarcinoma, SKCM: Skin cutaneous melanoma, STAD: Stomach adenocarcinoma, THCA: Thyroid carcinoma, UCEC: Uterine corpus endometrial carcinoma. |
| Top |
| Protein structure related information for PPP2R3B |
| Relative protein structure stability change (ΔΔE) using Mupro 1.1 Mupro score denotes assessment of the effect of mutations on thermodynamic stability. (ΔΔE<0: mutation decreases stability, ΔΔE>0: mutation increases stability) |
 : nsSNV at non-LBS : nsSNV at LBS |
 |
| nsSNVs sorted by the relative stability change of protein structure by each mutation Blue: mutations of positive stability change. and red : the most recurrent mutation for this gene. |
| LBS | AAchange of nsSNV | Relative stability change | D327 | T328M | -1.1628878 | D329 | T328M | -1.1628878 |
| (MuPro1.1: Jianlin Cheng et al., Prediction of Protein Stability Changes for Single-Site Mutations Using Support Vector Machines, PROTEINS: Structure, Function, and Bioinformatics. 2006, 62:1125-1132) |
| Structure image for PPP2R3B from PDB |
| Top |
| Differential gene expression and gene-gene network for PPP2R3B |
| Differential gene expression between mutated and non-mutated LBS samples in all 16 major cancer types |
| Differential co-expressed gene network based on protein-protein interaction data (CePIN) |
| Top |
| Top |
| Phenotype information for PPP2R3B |
| Gene level disease information (DisGeNet) |
| Disease ID | Disease name | # PubMed | Association type |
| Mutation level pathogenic information (ClinVar annotation) |
| Allele ID | AA change | Clinical significance | Origin | Phenotype IDs |
| Top |
| Pharmacological information for PPP2R3B |
| Gene expression profile of anticancer drug treated cell-lines (CCLE) Heatmap showing the correlation between gene expression and drug response across all the cell-lines. We chose the top 20 among 138 drugs.We used Pearson's correlation coefficient. |
 |
| Drug information targeting mutLBSgene (Approved drugs only) |
| Drug status | DrugBank ID | Name | Type | Drug structure |
| Gene-centered ligand-gene interaction network |
 |
| Ligands binding to mutated ligand binding site of PPP2R3B go to BioLip |
| Ligand ID | Ligand short name | Ligand long name | PDB ID | PDB name | mutLBS | CA | CALCIUM(2+) | 4i5l | B | D327 D329 | CA | CALCIUM(2+) | 4i5l | E | D327 D329 | CA | CALCIUM(2+) | 4i5n | E | D327 D329 | CA | CALCIUM(2+) | 4mew | A | D327 D329 |
| Top |
| Conservation information for LBS of PPP2R3B |
| Multiple alignments for Q9Y5P8 in multiple species |
| LBS | AA sequence | # species | Species | A407 | LDGDGALSMFE | 1 | Homo sapiens | A407 | LDGNGVITSNE | 1 | Arabidopsis thaliana | A407 | LDGDGVITPNE | 1 | Arabidopsis thaliana | D327 | KFWELDTDHDL | 1 | Homo sapiens | D327 | KFWELDGDHDC | 1 | Arabidopsis thaliana | D327 | RFWELDGDHDF | 1 | Arabidopsis thaliana | D329 | WELDTDHDLLI | 1 | Homo sapiens | D329 | WELDGDHDCFI | 1 | Arabidopsis thaliana | D329 | WELDGDHDFLI | 1 | Arabidopsis thaliana | D331 | LDTDHDLLIDA | 1 | Homo sapiens | D331 | LDGDHDCFIDK | 1 | Arabidopsis thaliana | D331 | LDGDHDFLIDK | 1 | Arabidopsis thaliana | D401 | WFRCMDLDGDG | 1 | Homo sapiens | D401 | WFKCVDLDGNG | 1 | Arabidopsis thaliana | D401 | WFKCIDLDGDG | 1 | Arabidopsis thaliana | D403 | RCMDLDGDGAL | 1 | Homo sapiens | D403 | KCVDLDGNGVI | 1 | Arabidopsis thaliana | D403 | KCIDLDGDGVI | 1 | Arabidopsis thaliana | D405 | MDLDGDGALSM | 1 | Homo sapiens | D405 | VDLDGNGVITS | 1 | Arabidopsis thaliana | D405 | IDLDGDGVITP | 1 | Arabidopsis thaliana | E412 | ALSMFELEYFY | 1 | Homo sapiens | E412 | VITSNEMQFFF | 1 | Arabidopsis thaliana | E412 | VITPNEMQFFY | 1 | Arabidopsis thaliana | L333 | TDHDLLIDADD | 1 | Homo sapiens | L333 | GDHDCFIDKDN | 1 | Arabidopsis thaliana | L333 | GDHDFLIDKEN | 1 | Arabidopsis thaliana |
 |
Copyright © 2016-Present - The University of Texas Health Science Center at Houston |